Brief: Tcr² Therapeutics Reports Third Quarter 2021 Financial Results
10/11/2021 11:58
Nov 10 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* EXPECT CASH ON HAND TO SUPPORT OPERATIONS THROUGH 2023
* PLANS TO FILE AN IND FOR TC-510, FIRST ENHANCED TRUC-T
CELL, IN
Q1 OF 2022
* QTRLY LOSS PER SHARE $0.69
* TO SELECT A LEAD CANDIDATE FOR ITS ALLOGENEIC PROGRAM IN
2022
* Q3 EARNINGS PER SHARE VIEW $-0.65 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX93lVgk
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview